# US 2024/0368257 A1 · Filamin a binding proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0368257 A1
- Document ID: US20240368257A1
- Status: Published application
- Kind: A1
- Application number: 18/523,239
- Filed: 2023-11-29
- Published: 2024-11-07
- Earliest claimed: 2016-11-01
- Assignees: BPGbio, Inc.
- Applicants: BPGbio, Inc.
- Inventors: Wenfang Sybil WU; Shobha Ravipaty; Tracey Friss; Viatcheslav R. Akmaev; Nikunj Narendra Tanna
- Web page: https://patentgrep.com/patent/US20240368257A1

## CPC

- C07K 16/18: against material from animals or humans
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- G01N 3/50: by measuring rolling friction, e.g. by rocking pendulum (G01N3/54 takes precedence)
- G01N 33/57555: of the prostate
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 27/623: combined with mass spectrometry
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2333/4742: Keratin; Cytokeratin
- G01N 2333/96455: Kallikrein (3.4.21.34; 3.4.21.35)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis or prostate cancer are also provided.

## Claims

### Claim at position 1

-96. (canceled)

### Claim 97

A method for detecting and/or quantifying the level of filamin A (FLNA) in a sample, comprising detecting and/or quantifying one or more surrogate peptides, wherein the one or more surrogate peptides comprise the amino acid sequence of SEQ ID NO:40 (P2) and/or SEQ ID NO:41 (P4).

### Claim 98 (depends on 97)

The method of claim 97, wherein the sample is blood, serum or plasma.

### Claim 99 (depends on 97)

The method of claim 97, wherein the sample is from a subject having or being suspected of having prostate cancer.

### Claim 100 (depends on 97)

The method of claim 97, wherein the one or more surrogate peptides are detected in a protein digest prepared from the sample using mass spectrometry

### Claim 101 (depends on 100)

The method of claim 100, wherein the mass spectrometry is multiple reaction monitoring (MRM) mass spectrometry.

### Claim 102 (depends on 101)

The method of claim 101, wherein the MRM is immunoprecipitation-multiple reaction monitoring (IPMRM) comprising a FLNA immunoprecipitation step.

### Claim 103 (depends on 102)

The method of claim 102, wherein the immunoprecipitation step is carried out using a protein that specifically binds to the sequence of SEQ ID NO: 35.

### Claim 104 (depends on 100)

The method of claim 100, wherein the range of detection for P2 is 62.5 pg/mL to 1500 pg/mL and the range of detection for P4 is 563 pg/mL to 27000 pg/mL.

### Claim 105 (depends on 97)

The method of claim 97, wherein a P2 internal standard (P2_IS) and/or a P4 internal standard (P4_IS) is also detected.

### Claim 106 (depends on 101)

The method of claim 101, wherein the MRM comprises monitoring one or more mass transitions m/z selected from the group consisting of: 441.7 (M+2H)2+→584.5 (y51+) for P2; 535 (M+3H)3+→832.4 (y81+) for P4, 445.5 (M+2H)2+→592.1 (y51+) for P2 internal standard (P2_IS), and 538.4 (M+3H)3+→842.5 (y81+) for P4 internal standard P4_IS.

### Claim 107 (depends on 97)

The method of claim 97, wherein the method comprises a FLNA immunoprecipitation step.

### Claim 108 (depends on 107)

The method of claim 107, wherein the immunoprecipitation step is carried out using a protein that specifically binds to the sequence of SEQ ID NO: 35.

### Claim 109 (depends on 103, 108)

The method of claim 103 or 108, wherein the protein is an antibody.

### Claim 110 (depends on 109)

The method of claim 109, wherein the antibody binds to an epitope comprising an amino acid sequence of ERPLVGV.
